Conversation with The Cancer Letter Gunsalus: Duke’s 4.5 Years is at the Extreme End of the Spectrum For a Misconduct Probe May 08, 2015Vol.41 No.18By Paul Goldberg
Conversation with The Cancer Letter A Doctor’s Plan to Save Personalized Medicine 2 May 08, 2015Vol.41 No.18By Paul Goldberg
Conversation with The Cancer Letter A Doctor’s Plan to Save Personalized Medicine May 08, 2015Vol.41 No.18By Paul Goldberg
Conversation with The Cancer Letter Wender: Mammography Guidelines Should Balance Benefits and Risks, Not Costs April 24, 2015Vol.41 No.16By Matthew Bin Han Ong
Conversation with The Cancer Letter Costs of Harm from Mammography Must Be Balanced Against Benefits April 24, 2015Vol.41 No.16By Matthew Bin Han Ong
Conversation with The Cancer Letter Dalton: I Don’t Know Another Place like ORIEN March 13, 2015Vol.41 No.10By Matthew Bin Han Ong
Conversation with The Cancer Letter ASCO CEO Allen Lichter Discusses CancerLinQ February 20, 2015Vol.41 No.07By Matthew Bin Han Ong
Conversation with The Cancer Letter Conti: Don’t Count on an 80% Price Drop From the Launch of Neupogen’s Biosimilar February 06, 2015Vol.41 No.05By Matthew Bin Han Ong
Conversation with The Cancer LetterFree Kramer: Our Cancer Risk is not Written in the Stars January 16, 2015Vol.41 No.02By Matthew Bin Han Ong
Conversation with The Cancer Letter Is Republican Control Better Than Two-Party Stalemate? December 19, 2014Vol.40 No.47By Matthew Bin Han Ong
